Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Richard Amerling

Dr. Richard Amerling MD

Director of Outpatient Dialysis, BETH ISRAEL MEDICAL CENTER (INC)

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Richard Amerling, MD, is Director of Outpatient Dialysis and Continuous Renal Replacement Therapy at Beth Israel Medical Center in New York City. Dr. Amerling has an extensive background in all aspects of consultative nephrology, including hypertension, kidney stones, glomerular diseases, diabetes, renal biopsy, and acute and chronic renal failure. He has written extensively about health care economics and politics and has been published in the New York Times, The Wall Street Journal, Investor's Business Daily, The National Review, Internal Medicine News, The Dialysis Times, and Nephrology News and Issues. (This is me - Update Profile)


Employment History

1990 - Unspecified
Director of Outpatient Dialysis, BETH ISRAEL MEDICAL CENTER (INC)

GLG NewsSM Analyses by Richard Amerling(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

The Dark Side of Fosamax

July 25, 2008

Drugs to Build Bones May Weaken Them | www.nytimes.com

Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.  

So Much for Health "Insurance"

July 10, 2008

Pricey Drugs Put Squeeze on Doctors | online.wsj.com

It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up.  The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event. 

Our Kids on Statins...........Not!

July 10, 2008

8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com

With the pipeline for new drugs running dry, it is no surprise that pharmaceutical companies are looking to expand indications for existing products still under patent protection.  What better way to do this than by creating entirely new patient populations out of whole cloth?

Leading institutions connect with Richard Amerling through GLG

GLG Live Meetings with Richard Amerling(?)

Richard Amerling has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare